Sirtex Medical

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Sirtex Medical sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials none currently recruiting 3 completed later-stage tilt upper quartile by trial count

Sirtex Medical: 6 sponsored US clinical trials, none currently recruiting.

Sirtex Medical sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is BCLC Stage A Hepatocellular Carcinoma, with 1 trials.

Upper-quartile sponsor footprint

Sirtex Medical sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

6 total, page 1 of 1

ACTIVE NOT RECRUITING NA

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

NCT04736121
COMPLETED Phase 4

SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA

NCT05848947
TERMINATED Phase 2

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

NCT02807181
COMPLETED Phase 3

FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

NCT01721954
TERMINATED NA

SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma

NCT00503867
COMPLETED NA

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

NCT00724503

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 1
Phase 4 1

Therapeutic Areas

BCLC Stage A Hepatocellular Carcinoma 1
BCLC Stage C Hepatocellular Carcinoma 1
BCLC Stage B Hepatocellular Carcinoma 1
Unresectable Hepatocellular Carcinoma 1

How the Sirtex Medical archive is shaped

6 indexed studies, none listed as recruiting (0% open); 3 completed (50%).

Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: BCLC Stage A Hepatocellular Carcinoma (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Sirtex Medical: archived-pipeline peers nationwide

Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Sirtex Medical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Sirtex Medical23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch10xBio22nd Century Group3-C Institute for Social Development3 Waves Wellness
Sirtex Medical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sirtex Medical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Sirtex Medical page

6 registered trials is a research-attention snapshot, not an endorsement of Sirtex Medical or any single study.

  • None of Sirtex Medical's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • BCLC Stage A Hepatocellular Carcinoma is the condition Sirtex Medical studies most, compare against other sponsors active in the same condition before evaluating a specific study. See BCLC Stage A Hepatocellular Carcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sirtex Medical pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.